SCHEMBL641763

SCHEMBL641763

CC(C)(C)OC(=O)N1CC(F)C[C@H]1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.42
NR1H2 P55055 1/20 0.39
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
ATM Q13315 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
HSD11B1 P28845 1/20 0.37
HTRA1 Q92743 1/20 0.36
BTK Q06187 1/20 0.35
DPP4 P27487 2/20 0.34
UCHL1 P09936 1/20 0.34
USP30 Q70CQ3 1/20 0.33
USP2 O75604 1/20 0.33
PEPD P12955 1/20 0.33
XPNPEP1 Q9NQW7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20811620 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL38017 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL17760125 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL192501 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL2489604 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL192921 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL1853822 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL29038999 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL1334717 0.87 NR1H2 (0.39) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL15116701 0.87 NR1H2 (0.39) HSD17B10NR1H2CHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114539118-A Novel process for synthesizing N-Boc-4-fluoro-L-proline 南京碳硅人工智能生物医药技术研究院有限公司 2022-05-27 CN claimed
WO-2026085629-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2026-04-30 WO disclosed
US-20250171400-A1 AZA-HETEROCYCLYL CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS X-BIOTIX THERAPEUTICS, INC. 2025-05-29 US disclosed
US-12227475-B2 Aza-heterocyclyl carboxamide and related compounds and their use in treating medical conditions X-BIOTIX THERAPEUTICS, INC. 2025-02-18 US disclosed
CN-119173253-A Combination of allosteric and orthosteric EGFR inhibitors for the treatment of cancer 豪夫迈·罗氏有限公司 2024-12-20 CN disclosed
CN-118525022-A Azacyclo derivative and application thereof in medicine 西藏海思科制药有限公司 2024-08-20 CN disclosed
CN-118339153-A Heteroaromatic compounds for the treatment of cancer 勃林格殷格翰国际有限公司 2024-07-12 CN disclosed
CN-114573491-B Process for preparing pyrrolidine amide derivatives 广东东阳光药业股份有限公司 2023-12-08 CN disclosed
EP-4255908-A1 NEW INDAZOLE ACETYLENE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2023-10-11 EP disclosed
EP-4255906-A1 NEW INDAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2023-10-11 EP disclosed
US-20120295884-A1 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2012-11-22 US disclosed
WO-2012093101-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2012-07-12 WO disclosed
EP-2464368-A1 CATHEPSIN C INHIBITORS Glaxo Group Limited (GB) 2012-06-20 EP disclosed
US-8119805-B2 Substituted disulfonamide compounds GRUENENTHAL GMBH (DE) 2012-02-21 US disclosed
WO-2012018534-A2 SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES SCHERING CORPORATION (US) 2012-02-09 WO disclosed
US-20110281870-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS ABBOTT LABORATORIES (US) 2011-11-17 US disclosed
EP-2380892-A1 IMIDAZOTHIAZOLE DERIVATIVE HAVING PROLINE RING STRUCTURE Daiichi Sankyo Company, Limited (JP) 2011-10-26 EP disclosed
JP-2011121872-A METHOD FOR PURIFYING OPTICALLY ACTIVE N-TERT-BUTOXYCARBONYL-TRANS-4-FLUOROPROLINE CENTRAL GLASS CO LTD 2011-06-23 JP disclosed
US-20100152158-A1 Substituted Disulfonamide Compounds GRUENENTHAL GMBH (DE) 2010-06-17 US disclosed
WO-2004032834-A2 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2004-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152158-A1 Substituted Disulfonamide Compounds BDKRB1, BDKRB2, BRS3 HSD17B10 3111/4885NR1H2 1408/4885CHRM2 309/4885
US-12227475-B2 Aza-heterocyclyl carboxamide and related compounds and their use in treating medical conditions AADAC, AZI2, CBX7 HSD17B10 2552/4885NR1H2 1699/4885CHRM2 3491/4885
US-20110281870-A1 NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS CACNA1C, ORAI1, CACNA1S HSD17B10 2971/4885NR1H2 2033/4885CHRM2 115/4885
US-20120295884-A1 Complement pathway modulators and uses thereof C5, C3AR1, C9 HSD17B10 2666/4885NR1H2 1256/4885CHRM2 945/4885
US-20250171400-A1 AZA-HETEROCYCLYL CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS AADAC, AZI2, CBX7 HSD17B10 2552/4885NR1H2 1699/4885CHRM2 3491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.